Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Blaine Mooers and Jie Wu.
Connection Strength

1.031
  1. The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. NPJ Precis Oncol. 2021 Jun 07; 5(1):48.
    View in: PubMed
    Score: 0.186
  2. Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol. 2021 06; 32(6):817-819.
    View in: PubMed
    Score: 0.182
  3. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021 02; 32(2):261-268.
    View in: PubMed
    Score: 0.178
  4. RET kinase alterations in targeted cancer therapy. Cancer Drug Resist. 2020; 3(3):472-481.
    View in: PubMed
    Score: 0.172
  5. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib. J Biol Chem. 2019 07 05; 294(27):10428-10437.
    View in: PubMed
    Score: 0.161
  6. Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol. 2018 09; 175(17):3504-3515.
    View in: PubMed
    Score: 0.152
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.